Table of Contents Author Guidelines Submit a Manuscript
International Journal of Nephrology
Volume 2014, Article ID 143426, 8 pages
Review Article

Anti-VEGF Cancer Therapy in Nephrology Practice

1Department of Nephrology, Pitie-Salpetriere Hospital, 75013 Paris, France
2Department of Nephrology, Monceau Park International Clinic, 75017 Paris, France

Received 24 February 2014; Accepted 11 August 2014; Published 24 August 2014

Academic Editor: Danuta Zwolinska

Copyright © 2014 Hassan Izzedine. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Expanded clinical experience with the antivascular endothelial growth factor (VEGF) agents has come with increasing recognition of their renal adverse effects. Although renal histology is rarely sought in antiangiogenic-treated cancer patients, kidney damage related to anti-VEGF is now established. Its manifestations include hypertension, proteinuria, and mainly glomerular thrombotic microangiopathy. Then, in nephrology practice, should we continue to perform kidney biopsy, and what should be done with the anti-VEGF agents in case of renal toxicity?